SynthesisJournal of diabetes investigation2016
Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.
Synthesis in Journal of diabetes investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Increased incidence of diabetes mellitus in hematological malignancies: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.Journal of diabetes investigation · 2016Pooled it
- Trial
- The Bidirectional Relationship Between Diabetes and Cancer: Mechanistic Insights, Epigenetic Intermediaries, and Therapeutic Approaches.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle-Aged but Not Older Men.Diabetes, obesity & metabolism · 2026Article
- Diabetes mellitus and health-related quality of life in long-term survivors of breast, colorectal or prostate cancer: a population-based prospective study.British journal of cancer · 2026Article
- The risk of new-onset type 2 diabetes and the influence of risk factors among men with prostate cancer in the Danish Diet, Cancer, and Health study.Journal of cancer survivorship : research and practice · 2026Article
- [Reassessing androgen deprivation therapy (ADT) in older men with advanced prostate cancer: when to use, when to discontinue, and role as monotherapy?]Urologie (Heidelberg, Germany) · 2026Review
- Influence of diabetes mellitus and anti-diabetic drugs on pathophysiology and prognosis for primary prostate cancer.International urology and nephrology · 2026Review
- Indian Delphi consensus on cardiovascular risk mitigation in prostate cancer management.Frontiers in oncology · 2026Review
- Diabetes Mellitus and the Prostate: The Odd Pairing.Cureus · 2025Review
- Risk of poor glycemic control in tamsulosin versus finasteride users with type 2 diabetes mellitus.Heliyon · 2025Article
- Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data.World journal of urology · 2023Article
- DAta Linkage to Enhance Cancer Care (DaLECC): Protocol of a Large Australian Data Linkage Study.International journal of environmental research and public health · 2023Article
- HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy.European urology open science · 2023Article
- Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.The Prostate · 2023Article
- Review
- Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionThere is still no obvious evidence proving that androgen deprivation therapy (ADT) would increase the risk of diabetes. To determine if ADT is associated with diabetes in men with prostate cancer, we carried out the present study. MATERIALS AND
methodsWe systematically searched Medline, Embase and the Cochrane Library Central Register through 2014. Studies comparing ADT vs control aimed at treating prostate cancer reporting diabetes as outcome were included. Data were extracted independently by two reviewers. This meta-analysis was reported based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses checklist. Observational studies were evaluated through the Meta-analysis Of Observational Studies in Epidemiology checklist.
resultsEight studies were identified with 65,695 ADT users and 91,893 non-ADT users. The pooled incidence of diabetes was 39% higher in ADT groups. A significant association was observed in the overall analysis (risk ratio [RR] 1.39, 95% confidence interval [CI] 1.27-1.53; P < 0.001). In subgroup analyses, diabetes was found to be significantly associated with gonadotropin-releasing hormone (GnRH) alone (RR 1.45, 95% CI 1.36-1.54; P < 0.001), GnRH plus oral antiandrogen (RR 1.40, 95% CI 1.01-1.93; P = 0.04) and orchiectomy (RR 1.34, 95% CI 1.20-1.50; P < 0.001), but not with antiandrogen alone (RR 1.33, 95% CI 0.75-2.36; P = 0.33). Diabetes was strongly related to long duration of ADT (RR 1.43, 95% CI 1.22-1.68; P < 0.001), and was slightly associated with short duration of ADT (RR 1.29, 95% CI 1.12-1.49; P = 0.0004).
conclusionsADT, especially long duration (>6 months) of this treatment, GnRH alone, GnRH plus antiandrogen and orchiectomy can increase the incidence of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.